Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

SABCS 2017: First-Line Ribociclib and Endocrine Therapy in Advanced Breast Cancer

By: Meg Barbor, MPH
Posted: Monday, December 11, 2017

The addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to first-line endocrine therapy significantly improved progression-free survival in pre- and perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer, with a manageable safety profile, according to data from the phase III MONALEESA-7 trial, presented by Debasish Tripathy, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, at the 2017 San Antonio Breast Cancer Symposium (SABCS; Abstract GS2-05).

“MONALEESA-7 is the first clinical trial to have the statistical power to show that ribociclib has clinical benefit specifically for pre- and perimenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer,” Dr. Tripathy reported. “It is also the first trial to show that ribociclib can be safely and effectively combined with either tamoxifen or a nonsteroidal aromatase inhibitor together with ovarian suppression using goserelin.”

A total of 672 patients who had received up to 1 line of chemotherapy and no prior endocrine therapy were randomized to treatment with either ribociclib in combination with tamoxifen or a nonsteroidal aromatase inhibitor (letrozole or anastrozole) and goserelin (n=335) or placebo in combination with the same oral hormonal therapy options and goserelin (n=337).

Median progression-free survival was significantly improved in the ribociclib arm: 23.8 months versus 13 months with placebo. The most frequent adverse event was neutropenia, reported in 76% of patients in the ribociclib arm compared with 8% in the placebo arm.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.